ReviewCannabis and cannabinoid research2022
Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol.
Review in Cannabis and cannabinoid research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Cannabinoid exposure across substance use disorders: Short-term symptom benefits without sustained therapeutic gains in a tier-weighted systematic review.European psychiatry : the journal of the Association of European Psychiatrists · 2026Pooled it
- Emerging preclinical evidence supports a potential role for cannabidiol in the management of sickle cell disease.Haematologica · 2026Review
- Self-reported cannabis use to manage opioid withdrawal symptoms and reductions in opioid use among people who use unregulated opioids: a cross-sectional analysis.Journal of cannabis research · 2026Article
- Combination of Cannabidiol and Low-Dose Buprenorphine Suggests Synergistic Analgesia and Attenuates Buprenorphine-Induced Respiratory Depression.Cannabis and cannabinoid research · 2025Article
- Effects of CB1 receptor negative allosteric modulator Org27569 on oxycodone withdrawal symptoms in mice.Psychopharmacology · 2024Article
- Use and perceptions of Cannabidiol among individuals in treatment for opioid use disorder.Harm reduction journal · 2024Article
- The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder.Pain and therapy · 2024Review
- The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management.Cureus · 2023Review
- Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Review
- Review
- Long-Term Treatment for Unspecified Anxiety Disorders with Cannabidiol: A Retrospective Case Series from Real-World Evidence in Colombia.Medical cannabis and cannabinoidsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.